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vein thrombosis
Werner Blättler, MD,a Georg Heller, MD,b Jon Largiadèr, MD,a Hannu Savolainen, MD,b
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Objective: In at least half of patients with iliofemoral deep vein thrombosis post-thrombotic syndrome develops when only
anticoagulant therapy is given. We combined thrombolysis, applied under ischemic conditions, with surgical thrombec-
tomy to restore patency and valve function. The technique and the short-term and long-term results in 2 patient series are
reported.
Methods: A catheter was inserted into a foot vein of the thrombosed leg, and the limb was excluded from the circulation
with a pneumatic cuff placed on the thigh with the patient under general anesthesia. Urokinase (0.5 million–3 million IU)
and heparin were infused and allowed to act for 30 minutes while the pelvic axis was cleared with a Fogarty catheter
through an inguinal venotomy. The external iliac vein was then clamped and the cuff removed. Thrombi that detached
from the wall were flushed out with reactive hyperemia and squeezed out with manual leg compression. The blood was
retrieved, washed, and transfused back into the patient. Various additional procedures were performed to secure outflow.
Two patient series are reported: 1 with 12 consecutive patients and 1 with 21 patients who were successfully treated 6 to
10 years previously. Follow-up data were obtained for all patients after 1 year and for 18 of 21 patients after 6 to 10 years.
Patency and valve function were assessed with duplex scanning or venography. Studies of blood coagulation and the
kinetics of urokinase were performed in 5 additional patients.
Results: Vein patency and valve function were restored in all consecutive patients. At 1 year none of the 33 patients had
had recurrence, and none showed clinical signs of post-thrombotic syndrome. At 6 to 10 years 3 of 18 patients had
experienced another venous thromboembolism, but none in the treated leg. Sixteen legs were asymptomatic without
compression therapy, and 2 had venous claudication. Coagulation studies showed a trace concentration of urokinase and
a mild decrease in fibrinogen in the systemic circulation. The concentration of urokinase in blood collected from the
treated leg was only 1% of that infused.
Conclusion: Regional thrombolysis combined with surgical thrombectomy is relatively easy to perform and seems safe.
Vein patency and valve function were restored, and post-thrombotic syndrome was prevented. Additional procedures to
overcome pelvic vein obstructions were required in 11 of 33 patients (33%). The procedure should be tested against
standard anticoagulation therapy in patients with acute iliofemoral thrombosis. ( J Vasc Surg 2004;40:620-5.)The immediate risks of acute deep vein thrombosis
(DVT) are effectively reduced with anticoagulation thera-
py.1 However, resolution of thrombi is slow and often
incomplete. Remaining thrombi harbor viable thrombin,
which may cause recurrences when anticoagulant is with-
drawn.2-4 They also obstruct outflow and impair valve
function, with ensuing venous reflux.5-7 Thus half of pa-
tients with a first proximal DVT sustain post-thrombotic
syndrome, with clinical signs and symptoms manifested as
soon as 6 months.8,9 To prevent these severe late sequela
strategies have been developed to dissolve or remove the
thrombi, including systemic thrombolysis, surgical throm-
bectomy, and catheter-directed thrombolysis. These meth-
ods all bear intrinsic risks, such as pulmonary embolism,
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morbidity. To date, the role of these techniques has not
been clearly established.10-14
We developed an intervention that combines regional
thrombolysis, applied under ischemic conditions, with
thrombectomy, with a primary success rate of 80%.15,16
This report includes 2 series of patients who underwent
this treatment, 1 with consecutive patients and 1 with
patients treated successfully 6 to 10 years previously, and a
study of the possible mechanism of action of the technique.
METHODS
Criteria for patient selection. Patients with severely
symptomatic, extensive proximal DVT were considered for
combined thrombolysis and thrombectomy when it
seemed likely that full restitution could be achieved with
the intervention and when they had no contraindications.
Patients with malignancy or other severe concomitant dis-
ease and patients with unknown duration of symptoms
were excluded. Thus candidates typically had a short history
of symptoms (1 week), a first episode of DVT, and
descending rather than ascending iliofemoral DVT (Table
I). Diagnosis was made with ascending venography or
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the vena cava was not routinely checked. Written informed
consent was obtained from all patients.
Interventional technique. The operative technique
was worked out by Dr Largiadèr in Lucerne and subse-
quently adopted with slight modifications in Bern by Dr
Schmidli and colleagues. The procedure is as follows. A
short 12-gauge catheter is introduced into a foot vein in the
thrombosed limb. With the patient under general anesthe-
sia the leg is elevated to empty the veins, and a large silicone
tourniquet cuff (Medizintechnik GmbH) is placed on the
thigh and inflated to 300 mm Hg to exclude the leg from
the systemic circulation. Urokinase HS (Medac), the puri-
fied enzyme from human urine, is infused into the leg
together with 5000 U of unfractionated heparin and up to
1000 mL of saline solution, distributed by means of leg
massage, and allowed to act for 30 minutes. Meanwhile the
common femoral vein is exposed and the proximal veins are
cleared with a Fogarty catheter, with use of standard tech-
niques. The femoral vein is then clamped proximal to the
venotomy, and the tourniquet is removed. The thrombi,
detached from the vein wall and partly degraded, are
flushed out by an enormous flow. The leg is massaged
again, from the foot to the thigh, to retrieve residual loose
clots. The blood is aspirated, washed, and transfused back
into the patient. The venotomy and the skin are closed.
Full-dose intravenous heparin, oral anticoagulants, and
compression treatment are started. In the case of persistent
proximal stenosis or occlusion, additional measures are
considered, such as deployment of a pelvic venous stent,
creation of an arteriovenous fistula, or insertion of a femo-
rofemoral crossover bypass, either immediately or later as a
separate intervention.
Table I. Patient characteristics in 2 study cohorts
Berne cohort
of consecutive
patients
Lucerne
cohort of
selected
patients
n % n %
No. of patients (female) 12 11 21 18
Age (y)
Median 23 25
Range 16-44 17-61
First vs recurrent DVT 12 0 19 2
Location, left vs right 10 2 17 4
Mean duration of symptoms (d) 3 3.5
Causes of DVT*
Idiopathic 2 3
Post surgery or trauma 5 5
Use of oral contraceptive pill 6 7
May-Thurner syndrome 2 5
Venous anomaly 0 1
Known genetic
thrombophilia
2 4
Other transient risk factors 2 4
DVT, Deep venous thrombosis.
*Multiple causes possible.Cohort of 12 consecutive patients. This prospective
survey of consecutive patients explored the short-term suc-
cess rate and safety of the procedure. Patients received
treatment at the Cardiovascular Centre of the University
Hospital of Bern (Inselspital), Switzerland, between May
2000 and February 2003. Demographic and clinical char-
acteristics are listed in Table I, and the extent of DVT is
shown in Fig 1. The dose of urokinase was uniformly 0.5
million IU. An arteriovenous fistula was created between a
branch of the greater saphenous vein and the common
femoral artery in 10 of 12 patients, and was closed after 6
months. In 4 patients an iliac stent (Wallstent) was placed
during surgery. Follow-up examination were performed 2
and 12 months after the intervention. Standard color-
coded duplex ultrasound techniques were used to assess
vein patency and function of the femoropopliteal valves.17
Cohort of 21 patients treated 6 to 10 years
previously. The purpose of this study was to assess the
long-term outcome in those patients who had undergone
successful combined thrombolyis and thrombectomy.
From a list of patients who received treatment at the
Kantonsspital in Lucerne, Switzerland, between January
1993 and August 1996 we searched for patients who
fulfilled the following criteria: symptoms for no more than
5 days before treatment, and complete restitution of the
venous system documented on normal postoperative as-
cending and descending venograms. In 2 patients, how-
ever, persistent occlusion of the common iliac vein was
noted on the venogram, which was initially interpreted as
normal. Patients with incomplete documentation were ex-
cluded. We identified 21 patients, and invited them for a
follow-up visit with a vascular physician by the end of 2003
or interviewed them by telephone if they could not come to
the clinic. Demographic and clinical characteristics are
listed in Table I, and extension of the DVT is shown in Fig
1. The dose of urokinase varied in these patients, from 0.5
million to 3 million IU. Femorofemoral bypass grafts were
inserted, with use of the contralateral greater saphenous
vein as a conduit in 4 patients and a polytetrafluoroethylene
crural popliteal femoral pelvic 
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Fig 1. Extent of thrombosis in 2 study cohorts.
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placed in 2 patients.
Assessment of haemostasis and kinetics of
urokinase. Parameters of coagulation were studied in 5
additional patients. These patients received an infusion of 3
million IU (43 mg) of urokinase. Three blood samples
were collected from the femoral vein, the first immediately
on loosening the tourniquet, the second 2 minutes later,
and the last before closure of the venotomy. Four samples
were obtained from the systemic circulation through a
central venous catheter before, duringn and at the end of
the intervention. The following assays were performed:
fibrinogen, with clotting time technique; plasminogen,
with an amidolytic assay; D-dimer, with an enzyme-linked
immunosorbent assay (ELISA); and urokinase, with an
ELISA (American Diagnostica). The concentration of
urokinase was measured in milligrams per milliliter, with 1
mg equal to 70,000 IU.
RESULTS
Early results and safety (Table II). The results of the
2 patient series are combined, because the main interven-
tion was the same: regional thrombolysis, applied under
ischemic conditions, combined with surgical thrombec-
tomy. In all patients thrombi in the proximal veins were
removed. An example of how the thrombi usually appear in
Table II. Interventional procedures and immediate
outcome
Berne cohort of
consecutive
patients
Lucerne cohort of
selected patients
No. of patients 12 21
Operating time (min)
Median 110 ND
Range 55-240 ND
Hospital stay (d)
Median 6 ND
Range 4-10 ND
Primary success 12 (100%) 21 (100%)
Early recurrence or repeat
procedures
2 2
Additional interventions 14 7
Femorofemoral venous
bypass
0 5
Stent placement 4 2
Arteriovenous fistula 10 0
Transfusion requirement 0 ND
Hematoma requiring
drainage
0 6
Systemic bleeding 0 0
Clinical pulmonary embolism 0 0
Other complications 0 ND
Postoperative assessment
Thrombi remaining in
proximal veins
0 0
Thrombi remaining in
crural veins
ND 1
Pelvic vein still occluded 0 3
ND, No data.the operating field is depicted in Fig 2. In each center 2
patients underwent repeat operation because of early prox-
imal recurrence. Placement of an iliac stent or a bypass
procedure was performed in conjunction with the second
thrombectomy. Before discharge all patients were exam-
ined with duplex scanning or ascending and descending
venography. Remaining crural thrombi were found in 1
patient, and iliac vein occlusion persisted in 3 patients. In 1
of these patients a stent was successfully placed later, and 2
patients were prescribed long-term anticoagulation ther-
apy. No deep venous reflux was documented in any patient.
No major technical problems or severe adverse events
were encountered in either center. No systemic bleeding
was observed, and no clinical suspicion of pulmonary em-
bolism was raised. Local hematoma requiring drainage
occurred in Lucerne, where urokinase was often used at a
higher dose.
Outcome 1 year after the intervention (both co-
horts; Table III). None of the 33 patients experienced
clinically apparent recurrence or a new venous thromboem-
bolism within the first year, even though anticoagulation
therapy was stopped in most patients. Clinical signs of
post-thrombotic syndrome were absent in all but 1 patient.
In this patient post-thrombotic syndrome was ascribed to
an earlier DVT. Leg compression had been prescribed for 6
months or less in most patients.
Outcome 6 to 10 years after intervention (Lucerne
cohort). Data from 18 of 21 patients (86%) were obtained
on average 8 years after treatment, and 15 patients were
examined by a physician. Three episodes of venous throm-
boembolism (17%) were documented, but none affected
the initially treated limb. Two patients had cutaneous signs
of chronic venous hypertension (CEAP C4), however, pre-
existing in 1 patient and located on the contralateral leg,
which was affected during follow-up. Venous claudication
Table III. Findings 1 year after intervention
Berne cohort
of consecutive
patients
Lucerne cohort
of selected
patients
No. of patients 12 21
Recurrence 1 0
Persistent pelvic vein
occlusion
1 2
Deep venous reflux 0 0
Duration of anticoagulant
therapy (mo)
3 0 5
3–6 11 6
6–12 1 8
ND — 2
Use of medical compression
stockings (mo)
None or  1 mo 0 8
3 0 5
6 12 3
12 0 3
ND — 2
ND, No data.
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and an occluded femorofemoral venous bypass, respec-
tively. Since the operation, 8 of 18 patients have had no
serious illnesses or injuries, but 10 had diseases including
diabetes (2 patients), polyarthronosis, inoperable heart dis-
ease, aneurysm of the thoracic aorta, sarcoidosis, vasculitis
with renal transplantation, and psychosis, and 2 patients
had multiple pregnancies with normal outcomes.
Hemostasis parameters and kinetics of urokinase.
In the systemic blood circulation a decrease in fibrinogen
was found, from 3.3 g/L (range, 2.3-4.8 g/L) before the
start of the operation to 1.55 g/L (range, 0.3-2.6 g/L) at
the end of the operation. No further decrease in fibrinogen
was observed. The D-dimer concentration increased, from
6.6 ng/mL (range, 3.3-11.6 ng/L) before the operation to
13.0 ng/mL (range, 9.3-20.0 ng/L) at the end of the
operation.
In the blood collected from the leg on loosening of the
tourniquet the concentration of fibrinogen was markedly
reduced (mean, 0.38 g/L; range, 0-0.8 g/L). Plasminogen
was also lowered, but not totally consumed (mean, 21%;
range, 14%-29%). A few minutes later, just before closure of
the venotomy, the average concentration of fibrinogen
returned to 1.42 g/L (range, 0.4-1.9 g/L) and plasmino-
gen level was 53% (range, 31%-82%).
Measurements of urokinase in blood are depicted in Fig
3. A small amount of urokinase (mean concentration, 1.83
mg/mL; range, 0.1-7.8 mg/mL) was found in systemic
blood during the procedure. After restoration of the circu-
lation a 10-fold increase was found, which, however, was
still 100 times lower than the concentration measured in
blood coming from the leg. But even this concentration
was only about 1% of that infused into the ischemic limb.
About 43 mg (corresponding to 3 million IU) of urokinase
was infused. If we assume a blood volume in the leg of 1 L
Fig 2. Usually, the thrombi appearing in the operating
demonstrate the completeness of the thrombectomy. Thand an even distribution of the drug, the calculated intra-
vascular concentration was about 43,000 mg/mL. How-
ever, the peak concentration in the first blood coming from
the leg averaged only 470 mg/mL.
are only partly degraded. Here, they are assembled to
pressions of the valves are depicted in the insert.
Fig 3. Urokinase concentration in blood collected from the sys-
temic circulation and the treated leg. The thrombosed leg was
excluded from the systemic circulation by means of a tourniquet
placed on the thigh, and infused through a foot vein with 3 million
IU of urokinase (43 mg). Systemic blood was collected from a
central venous catheter before (1) and during (2) the infusion, at
closure of the venotomy (5), and at the end of the operation (6).
Samples were obtained from the site of the inguinal venotomy
immediately on loosening the tourniquet (3), when clots appeared
no longer (4), and just before closure of the venotomy (5). Time
between collection of samples 1 and 3 was 30 minutes, and
between samples 3 and 6 was 30 to 45 minutes. Urokinase con-
centrations (mg/mL) are plotted on a logarithmic scale. Data are
from 5 patients (mean  1 SD).field
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In patients with extensive proximal DVT severe post-
thrombotic syndrome is likely to develop despite standard
anticoagulation therapy. Strategies to improve the out-
come have been designed, but the heuristic goals of restor-
ing both vein patency and valve competence were not
predictably achieved. Furthermore, they require a multidis-
ciplinary team of specialists, are time-consuming, and are
associated with important risks such as pulmonary embo-
lism and systemic bleeding.
We developed a relatively simple procedure to restore
both vein patency and valve function. Thrombolysis applied
to the leg excluded from the systemic circulation was
combined with surgical thrombectomy. The 2 patient se-
ries reported here provide evidence that the intervention
leads to complete clearance of thrombi from the proximal
veins and is devoid of severe complications. It was associ-
ated with neither pulmonary embolism, because the clots
were retrieved, nor systemic bleeding, inasmuch as the
thrombolytic agent exerted only minor systemic activity.
To prevent recurrence, remaining proximal occlusions were
treated with additional interventions, which were different
in the 2 cohorts. Inasmuch as the clinical results after 1 year
were equally good in both series, we assume that all meth-
ods effectively secured the outcome.
The retrospective survey of patients treated long ago
resolved 2 issues: in successfully treated patients post-
thrombotic syndrome does not develop, and DVT does not
recur in these legs. However, some patients may be prone
to further venous thromboembolism.
Laboratory studies were performed to elucidate the
specific features of the procedure. A decrease in systemic
fibrinogen and an increase in the D-dimers was found on
loosening the tourniquet. These transient changes were
ascribed to the inflow of blood, which contained no fibrin-
ogen but large amounts of D-dimers. We previously found
no further decrease in fibrinogen and therefore have no
evidence for ongoing systemic thrombolysis. However,
that traces of urokinase were found in systemic blood shows
that the tourniquet could not prevent some leakage. The
tightness of the tourniquet is the key prerequisite for a safe
intervention. The most astonishing finding, however, was
the low concentration of urokinase measured in the blood
coming from the leg. We recovered only 1% of the amount
infused. We speculated that urokinase had left the circula-
tion. We rejected the idea that it was degraded to the extent
that it would have lost almost all of its immunoreactivity. If
urokinase diffused into the surrounding tissue, it is not
surprising that it did not exert a systemic effect. Protracted
local activity, however, may occur and be responsible for
the low frequency of recurrence. Secondary thrombolysis of
remaining clots was occasionally documented. On the
other hand, ongoing thrombolysis may jeopardize hemo-
stasis. Indeed, most local hematomas occurred late after
hemostasis had been secured, and predominantly in pa-
tients who received a higher dose of urokinase.Ischemic exclusion of an extremity was used long ago
to reduce blood loss during surgery, and later was found to
produce persisting hyperemia.18,19 The infusion of pro-
caine into the empty veins of an extremity excluded from
the circulation was introduced by August Bier in 1908 to
achieve regional anesthesia.20 The same technique was used
to treat chronic leg ulcers with urokinase,21 and cruropop-
liteal DVT with recombinant tissue plasminogen activa-
tor.22 Studies performed long ago showed that drugs ad-
ministered in this way diffuse rapidly into areas that would
otherwise be difficult to reach, such as clots, ischemic
tissues, and skin ulcers.23,24
In summary, our technique seems to work. Local
thrombolysis, applied under ischemic conditions, com-
bined with surgical thrombectomy enables clearing of
thrombosed veins, preserves valve function, and retrieves
the thrombi. As repeatedly documented, remaining proxi-
mal occlusions should be resolved by placement of endo-
vascular stents or bypass. The intervention prevented de-
velopment of post-thrombotic syndrome, and selected
patients enjoyed long-lasting benefit. The technique
should be compared with standard anticoagulation therapy
in a randomized trial of patients with acute proximal DVT.
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